Disc Medicine opened lower at $86.16, compared with its previous close of $87.08. In the last trading session, the stock traded between $82.66 and $87.14. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Disc Medicine is now worth
$ 418.30
Giving a profit of
$ 318.30 (318.30%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-3.88 (-4.46%)
Day High
$87.14
Day Low
$82.66
Day Open
$86.16
Prev Close
$87.08
Volume
5,53,350
1W Return
-0.02%
1M Return
37.40%
3M Return
2.40%
6M Return
20.18%
1Y Return
-3.33%
Fundamentals
Market Cap ($ Mn)
3,789
PE Ratio
-
PB Ratio
4.76
PEG Ratio
-
ROE
-35.00%
ROCE
-37.08%
EPS (TTM)
$-1.54
Investment Returns
1 Week
-0.02%
1 Month
37.40%
3 Months
2.40%
6 Months
20.18%
9 Months
15.57%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
HC Wainwright raises Disc Medicine price target to $127, maintains Buy
HC Wainwright maintains a Buy rating on Disc Medicine. Price target raised from $120 to $127 by analyst Douglas Tsao. No change in the fundamental investment stance.
6 days ago
6Nov
Disc Medicine enters sales agreement with TD Cowen for $189.93M stock offering
Disc Medicine Inc. signed a sales agreement with TD Cowen. Common stock offering valued up to $189.93 million. Details disclosed in an SEC filing.
7 days ago
5Nov
Disc Medicine Q3 Results: Loss narrows to $1.53, beats estimate
Reported Q3 loss of $1.53 per share. Beat analyst consensus estimate of $1.76 by 13.07%. Improved from prior year Q3 loss of $1.77 per share. Year-over-year loss reduction stood at 13.56%.
7 days ago
21Oct
Disc Medicine prices upsized $450 million public stock offering
Disc Medicine priced an upsized public offering of $450 million in common stock. Shares sold at $75.00 each, totaling 6,000,000 units. Underwriters hold a 30-day option for an additional 900,000 shares. Proceeds will fund clinical development and commercialization of bitopertin.
23 days ago
20Oct
Morgan Stanley raises Disc Medicine price target to $92
Morgan Stanley raised the price target for Disc Medicine from $90 to $92. The investment bank maintained an Overweight rating on the stock. Analyst Sean Laaman authored the revised price target recommendation.
23 days ago
20Oct
Truist Securities raises Disc Medicine price target to $115
Truist Securities maintains Buy rating on Disc Medicine. Price target raised from $83 to $115. Analyst Danielle Brill issued the updated recommendation.
